DKMS gemeinnützige GmbH
Quick facts
Marketed products
- HAM · Oncology/Hematology
HAM is a hematopoietic stem cell mobilization and collection system used to facilitate autologous stem cell transplantation.
Phase 3 pipeline
- LDAC and/or Mitoxantrone · Oncology
LDAC (low-dose cytarabine) and mitoxantrone are chemotherapy agents that inhibit DNA synthesis and topoisomerase II, respectively, to kill rapidly dividing leukemic cells.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about DKMS gemeinnützige GmbH
What are DKMS gemeinnützige GmbH's marketed drugs?
Top marketed products include HAM.
What is DKMS gemeinnützige GmbH's pipeline?
DKMS gemeinnützige GmbH has 1 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include LDAC and/or Mitoxantrone.
Related
- HAM · Oncology/Hematology
- Sector hub: All tracked pharma companies